Loading
Everything OnCo dates to 2032: 5 entries, 3 landmarks and 2 expected dates. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
5 dated entries in OnCo fall in 2032: 3 landmarks and 2 expected dates.
Of those, 1 to the day, 1 to the month and 3 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Colorectal cancer. CIRCULATE-US (NRG-GI008, 1,912 estimated participants) has a primary completion date of 10 March 2029 and the French CIRCULATE (1,980 estimated) of March 2032; N...
Lung cancer (all types). ADRIATIC's study completion is listed for 23 October 2026, IMpower010 for 31 August 2027, FLAURA2 for 30 September 2027, LAURA for 29 October 2027, MARIPOS...
Prostate cancer. ProBio's study completion is listed for December 2026, PSMAddition for 11 February 2027, CAPItello-281 for 31 March 2027, TALAPRO-3 for 28 August 2027, PROTEUS for...
Dates a source states for something still to come: roadmap watch items, the readout calendar, company catalysts, and registry primary completion dates.
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...